RT Journal Article
SR Electronic
T1 Human Antibodies Targeting a Transporter Mediate Protection Against Tuberculosis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.17.20101451
DO 10.1101/2020.05.17.20101451
A1 Watson, Avia
A1 Li, Hao
A1 Ma, Bingting
A1 Weiss, Ronen
A1 Bendayan, Danielle
A1 Abramovitz, Lilach
A1 Mor, Michael
A1 Pinko, Erica
A1 Bar-Oz, Michal
A1 Wang, Zhenqi
A1 Du, Fengjiao
A1 Lu, Yu
A1 Rybniker, Jan
A1 Huang, Hairong
A1 Barkan, Daniel
A1 Xiang, Ye
A1 Javid, Babak
A1 Freund, Natalia T
YR 2020
UL http://medrxiv.org/content/early/2020/05/22/2020.05.17.20101451.abstract
AB Evidence has emerged that some healthy individuals with a history of exposure to Mycobacterium tuberculosis (Mtb) can develop protective antibody responses. However, it is not known whether patients with active tuberculosis elicit protective antibodies, and if they do, which bacterial antigens are targeted. To investigate the B cell responses during active infection, we generated a panel of monoclonal antibodies isolated from memory B cells of one patient. The antibodies, members of four distinct B cell clones, were directed against the Mtb phosphate transporter subunit PstS1. Antibodies p4–36 and p4–163 from two different B cell clones showed protective efficacy against Mtb and Mycobacterium bovis-BCG in an ex vivo human whole blood growth inhibition assay. Germline versions of p4–36 and p4–163 could no longer bind Mtb, implying that affinity maturation was vital for their activity. Crystal structures of p4–36 and a closely related clonal variant of p4–163, p4–170, complexed to PstS1 were determined at a resolution of 2.1Å and 2.4Å and revealed that the two antibodies recognize two distinctive epitopes on PstS1. As a proof of principle, p4–36 and p4–163 were used in a passive vaccination setting in aerosol Mtb-infected Balb/c mice, where both antibodies reduced bacterial lung burden by 50% after a single injection prior to Mtb infection. Our study shows that inhibitory B cell responses arise during active tuberculosis and identifies PstS1 as a target for elicitation of anti-Mtb antibodies.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialFor human Tuberculosis patients: protocols number 33.18. and 0058, for healthy human donors: 2014-2-25Funding StatementThis study was funded by Israeli Science Foundation grant 1422/18 to N. T. Freund and Israeli Innovation Authority grant 65029 to N. T. Freund, as well as a National Natural Science Foundation of China grant (81661128044) to B. Javid, who is a Welcome Trust InvestigatorAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall data associated with a paper is available, and can be accessed